Lyngby, Denmark

Claude Bonde

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 93(Granted Patents)


Company Filing History:


Years Active: 2009-2014

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Claude Bonde: Innovator in Pharmaceutical Compositions

Introduction

Claude Bonde is a notable inventor based in Lyngby, Denmark. He has made significant contributions to the field of pharmaceuticals, particularly in the development of stable formulations of peptides. With a total of 4 patents to his name, Bonde's work has had a substantial impact on the treatment of diabetes and related conditions.

Latest Patents

Bonde's latest patents include innovative pharmaceutical compositions designed for parenteral administration. One of his notable inventions is a stable formulation comprising insulinotropic peptides. Additionally, he has developed a pharmaceutical composition that combines a meal-related insulin peptide with an insulinotropic peptide, aimed at improving treatment outcomes for diabetes and bulimia.

Career Highlights

Claude Bonde is currently employed at Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care and other chronic conditions. His work at Novo Nordisk has allowed him to focus on advancing therapeutic options for patients, particularly through the development of peptide-based treatments.

Collaborations

Bonde has collaborated with several talented professionals in his field, including Dorthe Kot Engelund and Tina Bjeldskov Pedersen. These collaborations have contributed to the success of his research and the development of innovative pharmaceutical solutions.

Conclusion

Claude Bonde's contributions to the field of pharmaceuticals, particularly in peptide formulations, highlight his role as an influential inventor. His work continues to pave the way for advancements in diabetes treatment and patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…